Work

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology

Year: 2020

Type: article

Abstract: -ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the ass

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/fwfj-cm52

Authors: Ajani, Jaffer A., Al Benson,, Bartley, Angela N., Ventura, Christina B., Troxell, Megan, Kakar, Sanjay, Jain, Dhanpat, Ismaila, Nofisat, Washington, Mary Kay, Gulley, Margaret L., Tang, Laura, Mackay, Helen J., Colasacco, Carol, Carrato, Alfredo, Streutker, Catherine

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4299362640

FWCI: 0.091

Cites:

Cited by: 1

Related to: 10